57 related articles for article (PubMed ID: 23972664)
1. KLRG1, Another Opportunity for a Breakthrough in MTCL.
Varma G; Diefenbach CS
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38568191
[TBL] [Abstract][Full Text] [Related]
2. Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Toutah K; Nawar N; Timonen S; Sorger H; Raouf YS; Bukhari S; von Jan J; Ianevski A; Gawel JM; Olaoye OO; Geletu M; Abdeldayem A; Israelian J; Radu TB; Sedighi A; Bhatti MN; Hassan MM; Manaswiyoungkul P; Shouksmith AE; Neubauer HA; de Araujo ED; Aittokallio T; Krämer OH; Moriggl R; Mustjoki S; Herling M; Gunning PT
J Med Chem; 2021 Jun; 64(12):8486-8509. PubMed ID: 34101461
[TBL] [Abstract][Full Text] [Related]
3. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
Maurer B; Nivarthi H; Wingelhofer B; Pham HTT; Schlederer M; Suske T; Grausenburger R; Schiefer AI; Prchal-Murphy M; Chen D; Winkler S; Merkel O; Kornauth C; Hofbauer M; Hochgatterer B; Hoermann G; Hoelbl-Kovacic A; Prochazkova J; Lobello C; Cumaraswamy AA; Latzka J; Kitzwögerer M; Chott A; Janikova A; Pospíšilova Š; Loizou JI; Kubicek S; Valent P; Kolbe T; Grebien F; Kenner L; Gunning PT; Kralovics R; Herling M; Müller M; Rülicke T; Sexl V; Moriggl R
Haematologica; 2020; 105(2):435-447. PubMed ID: 31123029
[TBL] [Abstract][Full Text] [Related]
4. Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load.
Li HD; Cuevas I; Zhang M; Lu C; Alam MM; Fu YX; You MJ; Akbay EA; Zhang H; Castrillon DH
J Clin Invest; 2018 Aug; 128(9):4179-4191. PubMed ID: 30124468
[TBL] [Abstract][Full Text] [Related]
5. Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis.
Högstrand K; Darmanin S; Forshell TP; Grandien A
Oncotarget; 2018 Apr; 9(30):21396-21410. PubMed ID: 29765548
[TBL] [Abstract][Full Text] [Related]
6. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
[TBL] [Abstract][Full Text] [Related]
7. STAT5BN642H is a driver mutation for T cell neoplasia.
Pham HTT; Maurer B; Prchal-Murphy M; Grausenburger R; Grundschober E; Javaheri T; Nivarthi H; Boersma A; Kolbe T; Elabd M; Halbritter F; Pencik J; Kazemi Z; Grebien F; Hengstschläger M; Kenner L; Kubicek S; Farlik M; Bock C; Valent P; Müller M; Rülicke T; Sexl V; Moriggl R
J Clin Invest; 2018 Jan; 128(1):387-401. PubMed ID: 29200404
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
[TBL] [Abstract][Full Text] [Related]
9. Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS.
Cutucache CE; Herek TA
Front Oncol; 2016; 6():206. PubMed ID: 27725924
[TBL] [Abstract][Full Text] [Related]
10. Challenging perspectives on the cellular origins of lymphoma.
Malcolm TI; Hodson DJ; Macintyre EA; Turner SD
Open Biol; 2016 Sep; 6(9):. PubMed ID: 27683157
[TBL] [Abstract][Full Text] [Related]
11. Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Spinner S; Crispatzu G; Yi JH; Munkhbaatar E; Mayer P; Höckendorf U; Müller N; Li Z; Schader T; Bendz H; Hartmann S; Yabal M; Pechloff K; Heikenwalder M; Kelly GL; Strasser A; Peschel C; Hansmann ML; Ruland J; Keller U; Newrzela S; Herling M; Jost PJ
Leukemia; 2016 Jul; 30(7):1520-30. PubMed ID: 27055871
[TBL] [Abstract][Full Text] [Related]
12. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Zhong Y; Dong S; Strattan E; Ren L; Butchar JP; Thornton K; Mishra A; Porcu P; Bradshaw JM; Bisconte A; Owens TD; Verner E; Brameld KA; Funk JO; Hill RJ; Johnson AJ; Dubovsky JA
J Biol Chem; 2015 Mar; 290(10):5960-78. PubMed ID: 25593320
[TBL] [Abstract][Full Text] [Related]
13. Take (STAT)5: jazzing up T-cell leukemia.
Porcu P; Dubovsky J
Blood; 2014 Aug; 124(9):1383-4. PubMed ID: 25170111
[TBL] [Abstract][Full Text] [Related]
14. Models for mature T-cell lymphomas--a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts.
Warner K; Crispatzu G; Al-Ghaili N; Weit N; Florou V; You MJ; Newrzela S; Herling M
Crit Rev Oncol Hematol; 2013 Dec; 88(3):680-95. PubMed ID: 23972664
[TBL] [Abstract][Full Text] [Related]
15. Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology.
Herling M; Rengstl B; Scholtysik R; Hartmann S; Küppers R; Hansmann ML; Diebner HH; Roeder I; Abken H; Newrzela S; Kirberg J
Leuk Lymphoma; 2017 Apr; 58(4):788-796. PubMed ID: 27643643
[TBL] [Abstract][Full Text] [Related]
16. Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.
Heinrich T; Rengstl B; Muik A; Petkova M; Schmid F; Wistinghausen R; Warner K; Crispatzu G; Hansmann ML; Herling M; von Laer D; Newrzela S
Mol Ther; 2013 Jun; 21(6):1160-8. PubMed ID: 23609016
[TBL] [Abstract][Full Text] [Related]
17. Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis.
Haney SL; Hlady RA; Opavska J; Klinkebiel D; Pirruccello SJ; Dutta S; Datta K; Simpson MA; Wu L; Opavsky R
Oncogene; 2015 Oct; 34(43):5436-5446. PubMed ID: 25639876
[TBL] [Abstract][Full Text] [Related]
18. T-cell lymphoma: Microenvironment-related biomarkers.
Tse E; Kwong YL
Semin Cancer Biol; 2015 Oct; 34():46-51. PubMed ID: 26057207
[TBL] [Abstract][Full Text] [Related]
19. Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.
Ryan RJH; Wilcox RA
Hematol Oncol Clin North Am; 2019 Aug; 33(4):553-574. PubMed ID: 31229154
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
